449 related articles for article (PubMed ID: 22262486)
21. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
Wauters I; Vansteenkiste J
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
[TBL] [Abstract][Full Text] [Related]
22. The addition of oral iron improves chemotherapy-induced anemia in patients receiving erythropoiesis-stimulating agents.
Tan J; Du S; Zang X; Ding K; Ginzburg Y; Chen H
Int J Cancer; 2022 Nov; 151(9):1555-1564. PubMed ID: 35639027
[TBL] [Abstract][Full Text] [Related]
23. Epoetin alfa 40000 U once weekly and intravenous iron supply in solid tumor patients: early increase of hemoglobin level during chemotherapy.
Lalle M; Pistillucci G; Antimi M; D'Aprile M
J Exp Clin Cancer Res; 2005 Jun; 24(2):197-201. PubMed ID: 16110751
[TBL] [Abstract][Full Text] [Related]
24. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
25. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
[TBL] [Abstract][Full Text] [Related]
26. Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level.
Sanz Ortiz J
Clin Transl Oncol; 2008 Aug; 10(8):486-92. PubMed ID: 18667379
[TBL] [Abstract][Full Text] [Related]
27. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
[TBL] [Abstract][Full Text] [Related]
28. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
30. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
31. Venous thromboembolic events and erythropoiesis-stimulating agents: an update.
Dicato M
Oncologist; 2008; 13 Suppl 3():11-5. PubMed ID: 18458119
[TBL] [Abstract][Full Text] [Related]
32. Darbepoetin alfa and history of thromboembolic events.
Ferretti G; Felici A; Cognetti F
J Clin Oncol; 2009 Nov; 27(33):e211; author reply e212. PubMed ID: 19858373
[No Abstract] [Full Text] [Related]
33. Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron.
Kapoian T
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S21-8. PubMed ID: 19010258
[TBL] [Abstract][Full Text] [Related]
34. Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role?
Dahl NV; Henry DH; Coyne DW
Semin Dial; 2008; 21(3):210-1. PubMed ID: 18397204
[TBL] [Abstract][Full Text] [Related]
35. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.
Szucs TD; Blank PR; Schwenkglenks M; Aapro M
Oncology; 2011; 81(1):45-9. PubMed ID: 21921645
[TBL] [Abstract][Full Text] [Related]
36. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
[TBL] [Abstract][Full Text] [Related]
37. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
[TBL] [Abstract][Full Text] [Related]
38. Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia.
Muller RJ; Baribeault D
Am J Health Syst Pharm; 2007 Dec; 64(24):2547-56. PubMed ID: 18056942
[TBL] [Abstract][Full Text] [Related]
39. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
[TBL] [Abstract][Full Text] [Related]
40. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.
Hershman DL; Buono DL; Malin J; McBride R; Tsai WY; Neugut AI
J Natl Cancer Inst; 2009 Dec; 101(23):1633-41. PubMed ID: 19903808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
